Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines.

Kidd M, Drozdov I, Joseph R, Pfragner R, Culler M, Modlin I

Cancer1 Aug 2008Cited by 39 (Europe PMC)

PMID18618499PMCIDPMC2574930DOI10.1002/cncr.23700PepBankPUB-18618499

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

01LabIn vitro (cells)Activity measurement
In NCI-H720 cells, sensitivity to lanreotide was similar to sensitivity to BIM23120.
In plain wordsIn cells, lanreotide and BIM23120 produced similar sensitivity in NCI-H720 tumors.
Peptide
Lanreotide
Outcome
No significant changeAntiproliferative sensitivity versus BIM23120
Study
humann: not reported in source
NCI-H720 atypical bronchopulmonary neuroendocrine tumor cells
Comparator
BIM23120
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated
Source sentences
Summary
The atypical BP-NET, NCI-H720, was most sensitive to the sst(5) analog BIM23206 (half-maximal concentration, 2.4 pM) and demonstrated similar sensitivity to lanreotide and the sst(2) analog BIM23120.
1 context sentence(design, population, supporting numbers)
Summary · context
The cytotoxic effects of 12 somatostatin/dopamine compounds were evaluated in 3 NET cell lines, and real-time polymerase chain reaction and enzyme-linked immunoadsorbent assay studies were performed to delineate antiproliferative signaling pathways.
Report a problemFND-1861849901
02LabIn vitro (cells)Activity measurement
In KRJ-I cells, lanreotide was among the most potent tested analogs, with a reported concentration of 1 nM.
In plain wordsIn cells, lanreotide was among the most potent tested analogs against KRJ-I tumors, at a reported concentration of 1 nM.
Peptide
Lanreotide
Outcome
Not applicableAntiproliferative sensitivity
Study
humann: not reported in source
KRJ-I gastrointestinal neuroendocrine tumor cells
Outcome group
Tumor growth · Cancer
Studied dose
1 nMAs given in this study (human).
Measurements
Reported antiproliferative concentration
1 nM
lanreotide
Source sentences
Summary
The GI-NET, KRJ-I, was most sensitive to sst(2,5) analogs lanreotide (1 nM) and BIM23244 (7.4 nM).
1 context sentence(design, population, supporting numbers)
Summary · context
The cytotoxic effects of 12 somatostatin/dopamine compounds were evaluated in 3 NET cell lines, and real-time polymerase chain reaction and enzyme-linked immunoadsorbent assay studies were performed to delineate antiproliferative signaling pathways.
Report a problemFND-1861849902
03LabIn vitro (cells)Mechanism
In neuroendocrine tumor cells, lanreotide activated ERK-1/2 phosphorylation.
In plain wordsIn cells, lanreotide activated ERK-1/2 phosphorylation in neuroendocrine tumors.
Peptide
Lanreotide
Outcome
IncreaseERK-1/2 phosphorylation
Study
humann: not reported in source
Neuroendocrine tumor cell lines
Outcome group
Receptor activity and mechanism · Cancer
Studied dose
Dose not stated
Source sentences
Summary
Lanreotide activated extracellular signal regulated kinase-1/2 phosphorylation and p21(WAF1/CIP1) transcription, but inhibited Ki-67 transcription.
1 context sentence(design, population, supporting numbers)
Summary · context
The cytotoxic effects of 12 somatostatin/dopamine compounds were evaluated in 3 NET cell lines, and real-time polymerase chain reaction and enzyme-linked immunoadsorbent assay studies were performed to delineate antiproliferative signaling pathways.
Report a problemFND-1861849903
04LabIn vitro (cells)Mechanism
In neuroendocrine tumor cells, lanreotide activated p21 transcription.
In plain wordsIn cells, lanreotide activated p21 transcription in neuroendocrine tumors.
Peptide
Lanreotide
Outcome
Increasep21 transcription
Study
humann: not reported in source
Neuroendocrine tumor cell lines
Outcome group
Receptor activity and mechanism · Cancer
Studied dose
Dose not stated
Source sentences
Summary
Lanreotide activated extracellular signal regulated kinase-1/2 phosphorylation and p21(WAF1/CIP1) transcription, but inhibited Ki-67 transcription.
1 context sentence(design, population, supporting numbers)
Summary · context
The cytotoxic effects of 12 somatostatin/dopamine compounds were evaluated in 3 NET cell lines, and real-time polymerase chain reaction and enzyme-linked immunoadsorbent assay studies were performed to delineate antiproliferative signaling pathways.
Report a problemFND-1861849904
05LabIn vitro (cells)Mechanism
In neuroendocrine tumor cells, lanreotide inhibited Ki-67 transcription.
In plain wordsIn cells, lanreotide inhibited Ki-67 transcription in neuroendocrine tumors.
Peptide
Lanreotide
Outcome
DecreaseKi-67 transcription
Study
humann: not reported in source
Neuroendocrine tumor cell lines
Outcome group
Receptor activity and mechanism · Cancer
Studied dose
Dose not stated
Source sentences
Summary
Lanreotide activated extracellular signal regulated kinase-1/2 phosphorylation and p21(WAF1/CIP1) transcription, but inhibited Ki-67 transcription.
1 context sentence(design, population, supporting numbers)
Summary · context
The cytotoxic effects of 12 somatostatin/dopamine compounds were evaluated in 3 NET cell lines, and real-time polymerase chain reaction and enzyme-linked immunoadsorbent assay studies were performed to delineate antiproliferative signaling pathways.
Report a problemFND-1861849905

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.